# Datroway approved in the US for first-line triple-negative breast cancer after extending survival

Canonical page: https://technooptimist.io/stories/datroway-approved-in-the-us-for-first-line-triple-negative-breast-6f00b0bf
Date: 22 May 2026
About: [Daiichi Sankyo](https://technooptimist.io/companies/daiichi-sankyo.md) · [Datroway](https://technooptimist.io/biotech/datroway.md)
Original source: https://www.astrazeneca.com/media-centre/press-releases/2026/datroway-approved-in-us-for-1l-triple-negative-bc.html

The FDA approved Datroway for metastatic triple-negative breast cancer in patients who cannot receive PD-1/PD-L1 immunotherapy. In TROPION-Breast02, Datroway added five months of survival over chemotherapy, making it the only TROP2-directed conjugate to extend survival in this setting. It is Datroway's third US indication.

## Key facts

- 644 patients vs investigator's choice of chemotherapy.
- Overall survival HR 0.79 (+5.0 months, median about two years); progression-free survival HR 0.57.
- Response rate 64% vs 30%.
- Reviews under way in the EU, China and Japan and through Project Orbis.

---

The Techno Optimist tracks every frontier of technology, program by program: https://technooptimist.io/ (a Markdown version of any page: add .md to its URL; site map for agents: https://technooptimist.io/llms.txt).
Data API (JSON, realtime stream): https://technooptimist.io/developers. People read 5 pages free, then Reader $10/month; these Markdown pages are open to agents.